A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders
Latest Information Update: 06 Sep 2024
Price :
$35 *
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Topotecan
- Indications Acute myeloid leukaemia; Haematological malignancies; Leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Polycythaemia vera; Thrombocytosis
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2017 Results (n=95) assessing exposure-response analysis to inform the planning of a phase II trial published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 18 Mar 2017 Results assessing exposure-response analysis to inform the planning of a phase II trial, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 22 Aug 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research